Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III Randomized, Double-Blind, Placebo Controlled Multicenter Study to Determine the Safety and Efficacy of VI-0521 in the Treatment of Obesity in Adults With Obesity-Related Co-Morbid Conditions

Next Previous
X
Search
Trial Profile

A Phase III Randomized, Double-Blind, Placebo Controlled Multicenter Study to Determine the Safety and Efficacy of VI-0521 in the Treatment of Obesity in Adults With Obesity-Related Co-Morbid Conditions

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 10 Oct 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Phentermine/topiramate (Primary)
  • Indications Obesity
  • Focus Registrational; Therapeutic Use
  • Acronyms CONQUER

    • Most Recent Events

    • 07 Oct 2024 According to VIVUS media release, the company today announced the availability of QSIVA (phentermine and topiramate modified-release) in Sweden, Denmark, Finland, Iceland, Norway, and Poland, making QSIVA accessible to patients with overweight and obesity who could benefit from weight loss, The approval in the Scandinavian countries and Poland was supported by compelling Phase III clinical data from more than 3700 patients who participated in the EQUIP and CONQUER trials
    • 28 Apr 2017 Results (n=3040) assessing efficacy and safety of phentermine/topiramate extended release for weight loss in overweight and obese patients using pooled data from CONQUER, EQUIP and SEQUEL trials, published in the Diabetes Care
    • 24 Feb 2015 Results were presented as per Vivus Inc. media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top